{
  "item1": "ITEM 1. BUSINESS. leading creator manufacturer food, beverage, health & biosciences, scent pharma solutions complementary adjacent products, including natural health ingredients, which used wide variety consumer products. products sold principally manufacturers dairy, meat, beverages, snacks, savory, sweet, baked goods, grain processors other foods, personal care products, soaps detergents, cleaning products, perfumes, dietary supplements, food protection, infant, elderly animal nutrition, functional food, pharmaceutical oral care products.",
  "item7": "Pharma Solutions sales 2024 increased $16 million, 2% reported basis, $961 million compared $945 million 2023. currency neutral basis, Pharma Solutions sales also increased 2% 2024 compared 2023 period impact exchange rate variations flat. Performance Pharma Solutions operating segment driven volume growth industrial markets. Cost sales decreased $438 million $7.360 billion (64.1% sales) 2024 compared $7.798 billion (67.9% sales) 2023.",
  "item2": "Nine Months Ended September 30, (DOLLARS MILLIONS) Segment Comparable Currency Neutral Adjusted Operating EBITDA Health & Biosciences Impact Business Divestitures Impact Currency Fluctuation Depreciation & Amortization Restructuring Other Charges Impairment Goodwill Gains (Losses) Business Disposals Loss Assets Classified Held Sale Divestiture Integration Costs Strategic Initiatives Costs Gain Debt Extinguishment Entity Realignment Costs Income (Loss) Before Taxes Segment Comparable Currency Neutral Adjusted Operating EBITDA Margin: Health & Biosciences _____________________ Refer Note 6 reconciliation Adjusted Operating EBITDA Income (Loss) Before Taxes. Comparable portfolio results 2024 exclude impact divestitures. Impact business divestitures includes results F&E UK business divested September 1, 2024 (for September 2024), Pharma Solutions disposal group Nitrocellulose business divested May 1, 2025 May 9, 2025, respectively (for May 1, 2024 September 30, 2024 May 9, 2024 September 30, 2024, respectively). Currency neutral amounts calculated translating current year transaction amounts exchange rates corresponding prior year period."
}